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tal hypertensive gastropathy due to cirrhosis is a life-threatening
complication. During the last decades, mortality rates of variceal
bleeding in patients with cirrhosis have been falling, but portal
hypertensive bleeding continues to be amongst the leading
causes of death [1].
For primary prophylaxis of variceal bleeding, non-selective
beta blockade (NSBB) and endoscopic band ligation (EBL) are both
used as they are effective therapies [2,3]. Which therapy should
be the one of ﬁrst choice can be considered a controversy. How-
ever there are several issues that go beyond the initial assess-
ment of differences in survival, for which there are none or ﬁrst
bleeding, and for which EBL has a statistical advantage over
NSBB.
The safety of the endoscopic procedure is the ﬁrst consider-
ation. EBL can cause fatal iatrogenic bleeding [4,5], also reported
in the largest trial with the longest follow-up [6].The increased
expense and need for specialized staff of EBL compared to NSBB
is the second consideration. As mortality is not different between
therapies, the cost-effectiveness could be mainly related to the
cost of the extra variceal bleeding episodes in the NSBB treated
patients versus the equipment and staff costs for EBL. This has
been evaluated prospectively in trials comprising patients on
liver transplant waiting lists with mixed results, as a US trial
found a NSBB strategy more expensive [7] and a European trial
found the EBL to cost more [8]. Fatal iatrogenic bleeding was
not ‘‘costed” and it is unclear how it could be evaluated in such
an analysis. The third consideration is that EBL cannot prevent
bleeding from portal hypertensive gastropathy, which is the case
for NSBB [9]. The fourth consideration is that EBL has only been
evaluated in patients with medium/large varices. Patients with
small varices and severe liver disease are candidates for primary
prophylaxis [3]. In a single trial based on patients with contrain-
dications to NSBB, some of whom also had small varices, fatal iat-
rogenic bleeding occurred with EBL and the trial was stopped
prematurely [5]. Conversely NSBB are effective in patients with
small varices [10] and are effective independent of cause and
severity of cirrhosis, the presence of ascites and variceal sizeJournal of Hepatology 20
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tion amongst endoscopists is that NSBB are less effective in
patients with decompensated cirrhosis. Another common mis-
conception is an increased risk of hepatic encephalopathy with
administration of beta-blockers. This has not been documented
in placebo-controlled trials and is not a contraindication to
receiving beta-blockers.
A further consideration is that preventative therapy, particu-
larly in asymptomatic patients, should be easy to administer,
have few and no serious adverse effects, and be effective. NSBB
on paper fulﬁls these criteria better than EBL, but unfortunately
these aspects have not been evaluated in randomised compara-
tive studies. Although a survey on patient preferences in the pro-
phylactic setting has been published favouring EBL, the potential
iatrogenic bleeding with EBL was not part of the questionnaire
[12].
There are 16 randomised trials in patients with medium to
high risk varices comparing EBL to propranolol [6–8,13–25]. In
the meta-analysis of the 16 studies, EBL signiﬁcantly reduced
the risk of ﬁrst variceal bleeding compared to propranolol (rela-
tive risk difference 9.2%, 95% CI 5.2%-13.1%, and POR 0.5, 95% CI
0.37–0.68). However, mortality in the same meta-analysis was
not statistically different (POR 0.94, 95% CI 0.70–1.28). Recently,
nadolol and isosorbide mononitrate combined were found to
have similar efﬁcacy as EBL [26]. A summary of the meta-analyt-
ical data is set out in Table 1 and Fig. 1A and B. The number of
patients needing treatment with EBL to save one episode of
bleeding is 11 (95% CI 7–21 by random effects model). It requires
an average of three endoscopic sessions to eradicate varices, so
this means, on average 33 endoscopic procedures discounting fol-
low-up endoscopies after eradication. Conversely NSBB remains
cheap, as haemodynamic monitoring is not required in this set-
ting [27].
The important conclusion, when considering the merits of
NSBB or EBL for primary prophylaxis against variceal bleeding, is
that mortality is no different. Survival following variceal bleeding,
including that of more severely ill patients is improving [28]. As
several of the randomised trials were undertaken before the uni-
versal use of antibiotics, which improve survival in acute variceal
bleeding [3,29], it is likely that mortality from bleeding is already
better and will further improve. Moreover, data is emerging that
NSBB may also have other beneﬁcial therapeutic effects in
patients with cirrhosis, for example by reducing the risk of spon-
taneous bacterial peritonitis [30]. Improved survival with NSBB10 vol. 52 j 946–948
Table 1. Randomised controlled trials of banding ligation versus non-selective beta-blockers.
Study No. of patients Variceal bleeding ligation Variceal bleeding b-blockers Mortality ligation Mortality b-blockers
Chen 54 1/26 2/28 3/26 3/28
Sarin 99 4/45 12/44 5/45 5/44
De 30 2/15 1/15 NR NR
De la Mora 24 1/12 2/12 0/12 1/12
Song 61 6/31 7/30 5/31 8/30
Lui 100 3/44 9/66 11/44 18/66
Gheorge 53 3/25 13/28 1/25 5/28
Drastich 77 4/40 7/33 2/40 3/33
Schepke 152 19/75 22/77 34/75 33/75
Lo 100 8/50 13/50 12/50 11/50
Jutabha 62 0/31 6/31 0/31 4/31
Thuluvath 31 2/16 1/15 6/16 3/15
Psilopoulos 60 2/30 9/30 12/30 10/30
Abdelfattah 156 4/51 13/52 4/51 5/52
Lay 100 11/50 12/50 14/50 12/50
Norberto 62 2/31 3/31 3/31 3/31
JOURNAL OF HEPATOLOGYcompared to EBL has been shown in a long term follow up of a ran-
domised trial of secondary prophylaxis [31,32] leading to less
decompensation (other than bleeding), as well as in haemody-
namic responders in another secondary prophylaxis randomised
trial [33], and in pre-primary prophylaxis [34]. These potential
outcomes mean that NSBB could be the ‘‘aspirin” of hepatologists
[35,36]. Carvedilol may be more effective than propranolol – it
resulted in reduced rates of bleeding compared to EBL [37,38].
Compliance with NSBB and dealing with intolerance or side
effects is a problem encountered in clinical practice but is notChen
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Fig. 1. Forest plots for (A) ﬁrst bleeding (B) mortality in patients with cirrhosis an
blockers in randomised clinical trials (BB: beta-blockers, EBL: endoscopic band liga
Journal of Hepatology 201addressed in the randomised studies; increased compliance could
improve efﬁcacy, as in therapy for chronic hepatitis C. With
improved compliance, outcomes with NSBB might become even
better than reported at present.
We believe that NSBB should be ﬁrst line therapy for primary
prophylaxis of portal hypertensive bleeding in patients in cirrho-
sis, rather than EBL, as the reduction in bleeding risk is insufﬁ-
cient given the considerations discussed above. EBL should be
reserved for patients who have contraindications or true intoler-
ance to NSBB.Difference in percentage of bleeding
- 0.092 (- 0.053/ - 0.131)
Better EBL Better BB
- 75.00 - 50.00 - 25.00 0.00 25.00 50.00 75.00
66/0.675)
etter BB
Odds ratio
0.934 (0.692/1.262)
Better BB
1/16 1/4 1 4 16 64
d varices receiving either endoscopic banding ligation or non-selective beta-
tion).
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Why is this strategy not universally applied? Some reasons
have been already discussed, but an additional explanation could
be the remuneration in health care systems. EBL is paid for, on a
per procedure basis, whereas NSBB does not have a speciﬁc cost
code. If it does, the cost of propranolol 80 mg twice a day, for
12 months is only £21.46 (less than 25 Euros), so even including
dispensing costs, this is likely to be one of the cheapest and cost
effective therapeutic strategies in any branch of Medicine!
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